Original Research
Published on 16 May 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
in Breast Cancer

- 13,926 views
- 4 citations